IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics-Reference-Cited by-同舟云学术

IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics

Published:2012-07-04 Issue:7413 Volume:488 Page:656-659
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Sasaki Masato,Knobbe Christiane B.,Munger Joshua C.,Lind Evan F.,Brenner Dirk,Brüstle Anne,Harris Isaac S.,Holmes Roxanne,Wakeham Andrew,Haight Jillian,You-Ten Annick,Li Wanda Y.,Schalm Stefanie,Su Shinsan M.,Virtanen Carl,Reifenberger Guido,Ohashi Pamela S.,Barber Dwayne L.,Figueroa Maria E.,Melnick Ari,Zúñiga-Pflücker Juan-Carlos,Mak Tak W.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature11323.pdf

Reference34 articles.

1. Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807–1812 (2008)

2. Mardis, E. R. et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058–1066 (2009)

3. Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739–744 (2009)

4. Xu, W. et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17–30 (2011)

5. Figueroa, M. E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553–567 (2010)

Cited by 443 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epigenetic-modifying agents: the potential game changers in the treatment of hematologic malignancies;Critical Reviews in Oncology/Hematology;2024-09

2. The Leukemic Isocitrate Dehydrogenase (IDH) 1/2 Mutations Impair Myeloid and Erythroid Cell Differentiation of Primary Human Hematopoietic Stem and Progenitor Cells (HSPCs);Cancers;2024-07-27

3. Overlapping Stromal Alterations in Myeloid and Lymphoid Neoplasms;Cancers;2024-05-30

4. IDH inhibition in gliomas: from preclinical models to clinical trials;Nature Reviews Neurology;2024-05-17

5. Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors;Current Treatment Options in Oncology;2024-05-02